ANIP Q3 2022 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$84M+61.0% YoY

Gross Profit

$51M60.8% margin

Operating Income

-$5M-6.0% margin

Net Income

-$9M-10.3% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

-$6M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$739M

Total Liabilities

$402M

Stockholders' Equity

$337M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$52M	+61.0%
Gross Profit	$51M	$28M	+84.2%
Operating Income	-$5M	-$4M	-40.2%
Net Income	-$9M	-$4M	-93.4%

Revenue Segments

Generics, Established Brands, and Other

$71M85%

Rare Disease

$13M15%

Geographic Segments

United States

$83M99%

Canada

$970,0001%